Microbot Medical Inc. announced on February 11, 2025, the closing of its previously announced registered direct offering. The offering involved the purchase and sale of 6,103,289 shares of the company’s common stock at a price of $2.13 per share.
In a concurrent private placement, the company also issued unregistered short-term series I preferred investment options. These options allow for the purchase of up to 12,206,578 shares of common stock at an exercise price of $2.13 per share, exercisable for two years following stockholder approval.
The gross proceeds to Microbot Medical from these offerings were approximately $13 million, before deducting placement agent fees and other offering expenses. The net proceeds are designated for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System, as well as for working capital and general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.